A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Cancer Immunology, Immunotherapy.
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.
Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?.
Biochemical Society Transactions.
Immune Regulation by Pericytes: Modulating Innate and Adaptive Immunity.
Frontiers in Immunology.
Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains.
Role of nucleotide‐binding oligomerization domain 1 (NOD1) in pericyte‐mediated vascular inflammation.
Journal of Cellular and Molecular Medicine.
Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies.
In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement.
Microencapsulation of therapeutic bispecific antibodies producing cells: immunotherapeutic organoids for cancer management.
Journal of Drug Targeting.
Selection strategies for anticancer antibody discovery: searching off the beaten path.
Trends in Biotechnology.
The coming of age of engineered multivalent antibodies.
Drug Discovery Today.
Efficient production of single-chain fragment variable-based N-terminal trimerbodies in Pichia pastoris.
Microbial Cell Factories.
Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications..